← Leaderboards
Bulent Ozpolat
University Of Texas At Austin
$4,172,713
Attributed
$7,496,225
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,496,225 · 6
By mechanism
R01$6,366,974 · 3
R21$1,129,251 · 3
Top collaborators
- George A. Calin5 shared
- Vittorio Cristini5 shared
- Zhihui Wang5 shared
- Gabriel Lopez-Berestein4 shared
- Kevin N Dalby2 shared
- Anirban Maitra2 shared
Others in their field
Top investigators on “Tumor Growth”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,387,105
- Israel David Goldman · Yeshiva University$49,502,983
- Candace S Johnson · University Of Pittsburgh At Pittsburgh$44,839,363
- C Kent Osborne · Baylor College Of Medicine$40,237,256
- Alan F Horwitz · University Of Virginia Charlottesville$39,846,480
- Douglas Yee · University Of Minnesota$38,475,268
Research focus
Tumor GrowthTumorIn VivoIn VitroCellsTherapeutic TargetChemotherapyAptamerTargeted TreatmentReceptorMediatingMalignant NeoplasmsBasePharmaceutical PreparationsNeoplasm MetastasisDoseToxic EffectSmall Interfering RnaTumor MicroenvironmentMolecularNanotherapeuticNanoparticleMolecular TargetCancer Therapy
Grant awards (21)
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$398,024
R01 · FY2025 · CA
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$378,124
R01 · FY2024 · CA
Novel Targeted Therapeutics for Breast Cancer$351,075
R01 · FY2024 · CA · contact PI
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$390,063
R01 · FY2023 · CA
Novel Targeted Therapeutics for Breast Cancer$362,163
R01 · FY2023 · CA · contact PI
miR-155 targeted therapeutics for precision medicine in lung cancer$501,986
R01 · FY2022 · CA
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$390,063
R01 · FY2022 · CA
Novel Targeted Therapeutics for Breast Cancer$377,538
R01 · FY2022 · CA · contact PI
miR-155 targeted therapeutics for precision medicine in lung cancer$512,229
R01 · FY2021 · CA
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer$413,399
R01 · FY2021 · CA
Novel Targeted Therapeutics for Breast Cancer$370,575
R01 · FY2021 · CA · contact PI
miR-155 targeted therapeutics for precision medicine in lung cancer$512,231
R01 · FY2020 · CA
Novel Targeted Therapeutics for Breast Cancer$370,575
R01 · FY2020 · CA · contact PI
miR-155 targeted therapeutics for precision medicine in lung cancer$502,255
R01 · FY2019 · CA
miR-155 targeted therapeutics for precision medicine in lung cancer$536,674
R01 · FY2018 · CA
Targeting Kras in Pancreatic Cancer$208,800
R21 · FY2016 · CA · contact PI
Targeting Kras in Pancreatic Cancer$174,000
R21 · FY2015 · CA · contact PI
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer$168,781
R21 · FY2014 · CA · contact PI
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer$208,800
R21 · FY2013 · CA · contact PI
Novel Therapeutics for Translation Control in Breast Cancer$156,070
R21 · FY2013 · CA
Novel Therapeutics for Translation Control in Breast Cancer$212,800
R21 · FY2012 · CA